Tuesday, March 17, 2026

Cryptocurrency Executive Given Second Prison Term for Espionage Tied to North Korea

A cryptocurrency exchange executive was sentenced to four years for espionage, collaborating with a North Korean agent for military secrets.

Is DD01 the Future of MASH Treatment? Insights from D&D Pharmatech’s JP Morgan Presentation

D&D Pharmatech's CEO highlights growth in K-bio at JPM Healthcare Conference, unveiling promising drug data and future plans for clinical trials.

Will North Korea’s New 5-Year Plan Feed the Nation? Kim Jong-un’s Upcoming Party Meeting

North Korea plans a December plenary meeting to assess its five-year plan, with a significant congress expected next year to shape foreign policy.

Tag: Dupixent

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

GI Innovation Uses AI to Develop Next-Gen Allergy Drug Aimed at Dupixent’s $15 Billion Market

GI Innovation is advancing an AI-optimized allergy treatment, targeting multiple pathways in atopic dermatitis to rival Dupixent.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.